Last fall, FDA safety officers began compiling a list of children possibly killed by COVID vaccines. Digging through ...

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

The promising new vaccine reduced the risk of melanoma returning by 42%. A UVA Health researcher explains why the results ...

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 ...

Discover how the new personalized cancer vaccine intismeran combined with Keytruda lowers melanoma relapse risk, achieving an 82% 2-year survival rate.

Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...